GM-CSF is a promising therapeutic target in the treatment of rheumatoid arthritis–an autoimmune disease characterized by joint inflammation which can lead to local and systemic osteoporosis (Goldring and Gravallese, 2000; Avci et al., 2016; Guo et al., 2019). The gene discussed is CSF2; the disease is osteoporosis.